Thymidylate synthase inhibitors
Thymidylate synthase (TS) is a critical enzyme for DNA replication and cell growth because it is the only de novo source of thymine nucleotide precursors for DNA synthesis. TS is the primary target of 5-fluorouracil (5-FU), which has been used for cancer treatment for more than 40 years. However, di...
Saved in:
Published in | Seminars in oncology Vol. 26; no. 6; p. 621 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
01.12.1999
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Thymidylate synthase (TS) is a critical enzyme for DNA replication and cell growth because it is the only de novo source of thymine nucleotide precursors for DNA synthesis. TS is the primary target of 5-fluorouracil (5-FU), which has been used for cancer treatment for more than 40 years. However, dissatisfaction with the overall activity of 5-FU against the major cancers, and the recognition that TS still remains an attractive target for anticancer drugs because of its central position in the pathway of DNA synthesis, led to a search for new inhibitors of TS structurally analogous to 5,10-methylenetetrahydrofolate, the second substrate of TS. TS inhibitory antifolates developed to date that are in various stages of clinical evaluation are ZD 1694 and ZD9331 (Astra-Zeneca, London, UK), (Eli Lilly, Indianapolis, IN), LY231514 (BW1843U89 (Glaxo-Wellcome, Research Triangle Park, NC), and AG337 and AG331 (Agouron, La Jolla, CA). Although each of these compounds has TS as its major intracellular site of action, they differ in propensity for polyglutamylation and for transport by the reduced folate carrier. LY231514 also has secondary target enzymes. As a result, each compound is likely to have a different spectrum of antitumor activity and toxicity. This review will summarize the development and properties of this new class of TS inhibitors. |
---|---|
AbstractList | Thymidylate synthase (TS) is a critical enzyme for DNA replication and cell growth because it is the only de novo source of thymine nucleotide precursors for DNA synthesis. TS is the primary target of 5-fluorouracil (5-FU), which has been used for cancer treatment for more than 40 years. However, dissatisfaction with the overall activity of 5-FU against the major cancers, and the recognition that TS still remains an attractive target for anticancer drugs because of its central position in the pathway of DNA synthesis, led to a search for new inhibitors of TS structurally analogous to 5,10-methylenetetrahydrofolate, the second substrate of TS. TS inhibitory antifolates developed to date that are in various stages of clinical evaluation are ZD 1694 and ZD9331 (Astra-Zeneca, London, UK), (Eli Lilly, Indianapolis, IN), LY231514 (BW1843U89 (Glaxo-Wellcome, Research Triangle Park, NC), and AG337 and AG331 (Agouron, La Jolla, CA). Although each of these compounds has TS as its major intracellular site of action, they differ in propensity for polyglutamylation and for transport by the reduced folate carrier. LY231514 also has secondary target enzymes. As a result, each compound is likely to have a different spectrum of antitumor activity and toxicity. This review will summarize the development and properties of this new class of TS inhibitors. |
Author | Swenson, S Danenberg, P V Malli, H |
Author_xml | – sequence: 1 givenname: P V surname: Danenberg fullname: Danenberg, P V organization: Department of Biochemistry and Molecular Biology, USC/Norris Cancer Center, University of Southern California School of Medicine, Los Angeles, USA – sequence: 2 givenname: H surname: Malli fullname: Malli, H – sequence: 3 givenname: S surname: Swenson fullname: Swenson, S |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10606255$$D View this record in MEDLINE/PubMed |
BookMark | eNo1zstuwjAQQFEvQOVRfqHlByKNJ3gcLytUHhJSN3SNxvFEMSIhitNF_r4LYHV3R3ehJu29lYmaA7g8s9ZsZmqR0hUAtUV8UzMNBITGzNXnuR6bGMYbD7JOYzvUnGQd2zr6ONz79K6mFd-SrJ5dqt_d93l7yE4_--P265R1CHbIHBAV1he6NIYtVaTLgCWTY5EqFEQ6iATjfAUbCORzzAuPzqBhFpsLLtXHw-3-fCPh0vWx4X68vE7xH335OpY |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 10606255 |
Genre | Journal Article Review |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1P~ 3O- 4.4 457 4CK 53G 5RE AAEDW AALRI AAQOH AAQQT AAQXK AAWTL AAXUO ABFRF ABJNI ABOCM ABUDA ACGFO ADBBV ADMUD AEFWE AENEX AEVXI AFCTW AFETI AFFNX AFJKZ AFRHN AFTJW AGHFR AGRDE AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IH2 J5H K-O L7B MJL N4W NPM O9- OC~ OO- P2P R2- RIG ROL SEL SES SJN TWZ UDS X7M Z5R ZGI ZXP |
ID | FETCH-LOGICAL-p207t-906687b81c55a76f61cd2ca69aeefd8661deed59bf040d6b3238b29525aae73e2 |
ISSN | 0093-7754 |
IngestDate | Sat Sep 28 08:37:25 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p207t-906687b81c55a76f61cd2ca69aeefd8661deed59bf040d6b3238b29525aae73e2 |
PMID | 10606255 |
ParticipantIDs | pubmed_primary_10606255 |
PublicationCentury | 1900 |
PublicationDate | 1999-12-01 |
PublicationDateYYYYMMDD | 1999-12-01 |
PublicationDate_xml | – month: 12 year: 1999 text: 1999-12-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Seminars in oncology |
PublicationTitleAlternate | Semin Oncol |
PublicationYear | 1999 |
SSID | ssj0021722 |
Score | 1.9349018 |
SecondaryResourceType | review_article |
Snippet | Thymidylate synthase (TS) is a critical enzyme for DNA replication and cell growth because it is the only de novo source of thymine nucleotide precursors for... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 621 |
SubjectTerms | Animals Antimetabolites, Antineoplastic - pharmacology Antimetabolites, Antineoplastic - therapeutic use Colorectal Neoplasms - drug therapy Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Folic Acid - analogs & derivatives Folic Acid - pharmacology Folic Acid - therapeutic use Folic Acid Antagonists - pharmacology Folic Acid Antagonists - therapeutic use Glutamates - pharmacology Glutamates - therapeutic use Guanine - analogs & derivatives Guanine - pharmacology Guanine - therapeutic use Humans Indoles - pharmacology Indoles - therapeutic use Isoindoles Pemetrexed Quinazolines - pharmacology Quinazolines - therapeutic use Thiophenes - pharmacology Thiophenes - therapeutic use Thymidylate Synthase - antagonists & inhibitors |
Title | Thymidylate synthase inhibitors |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10606255 |
Volume | 26 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA5OQXwR73ftg28S2dLm0kcRZQgbwjbY20ialBW2bg8Fmb_ekzY1VRQvL6UkJTT5ysl3TnO-g9C1AgrajtIYS644joQhWIVGYZYCWRDU_pizicK9PuuOoqcxHfsaRWV2SaFuk9cv80r-gyq0Aa42S_YPyL4PCg1wD_jCFRCG6y8xXs0zvZoBX7TSA8UUtqSbLJ9mKrNFdJrEc2BFRMCJtfGNRZ58CKYD8v6c17M_9tqTs5kval3GYV5MnSw28PGCUmPAn71wNjAOsdW9a9rAKmvdYd00aKzKX24s5nJeria4km3wnejPvZ_0rOuuFmpxYW1S38ZXnIvccdKV9TtaTVf3_CfeX-7_wx207Yh7cFehsIvWTL6HNnvuaMI-umqAEdRgBB6MAzR6fBjed7GrPoGXpM0LHAMZE1yJTkKp5CxlnUSTRLJYGpNqAbxGA7-gsUrBDmqmQiA_isSUUCkNDw05ROv5IjfHKIgMDCQpUTFRUcLARzRAPLXucKGNCPkJOqqmNllWEiOTetKn3_acoS2P7jnaSOGbNhdAkAp1Wa7pGxTFESI |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thymidylate+synthase+inhibitors&rft.jtitle=Seminars+in+oncology&rft.au=Danenberg%2C+P+V&rft.au=Malli%2C+H&rft.au=Swenson%2C+S&rft.date=1999-12-01&rft.issn=0093-7754&rft.volume=26&rft.issue=6&rft.spage=621&rft_id=info%3Apmid%2F10606255&rft_id=info%3Apmid%2F10606255&rft.externalDocID=10606255 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0093-7754&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0093-7754&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0093-7754&client=summon |